Literature DB >> 23235124

Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation.

Bodil Sjöberg1, A Rashid Qureshi, Björn Anderstam, Anders Alvestrand, Peter Bárány.   

Abstract

BACKGROUND/AIMS: The purpose of this investigation was to determine if the long pentraxin 3 (PTX-3) may be a useful marker of intradialytic inflammation since it is rapidly released in the vasculature.
METHODS: PTX-3, interleukin-6, tumor necrosis factor-α and C-reactive protein were measured before and during a hemodialysis session in 22 patients and compared with healthy subjects. The effect of dialysis with low-flux, high-flux membranes and hemodiafiltration on the inflammatory response was compared in 11 patients.
RESULTS: C-reactive protein and interleukin-6 levels did not change, while a modest decrease in tumor necrosis factor-α was observed during hemodialysis. The plasma PTX-3 concentration was significantly increased (p < 0.001) after 60 min and peaked at 180 min during hemodialysis. There was no difference in the intradialytic increase in PTX-3 using different dialysis membranes and modalities.
CONCLUSION: PTX-3 stands out as a rapid and sensitive marker of hemodialysis-induced inflammation. Membrane flux and hemodiafiltration did not alter the inflammatory response.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23235124     DOI: 10.1159/000342630

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  9 in total

1.  Changes in cerebral oxygenation and cerebral blood flow during hemodialysis - A simultaneous near-infrared spectroscopy and positron emission tomography study.

Authors:  Harmke A Polinder-Bos; Jan Willem J Elting; Marcel Jh Aries; David Vállez García; Antoon Tm Willemsen; Peter J van Laar; Johanna Kuipers; Wim P Krijnen; Riemer Hja Slart; Gert Luurtsema; Ralf Westerhuis; Ron T Gansevoort; Carlo Ajm Gaillard; Casper Fm Franssen
Journal:  J Cereb Blood Flow Metab       Date:  2018-12-12       Impact factor: 6.200

2.  A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?

Authors:  Nicola Tessitore; Albino Poli; Valeria Bedogna; Luca Corazza; Natascia Campostrini; Mauro Atti; Luisa Sereni; Annalisa Castagna; Domenico Girelli; Giuseppina Pessolano; Antonio Lupo
Journal:  J Nephrol       Date:  2017-03-28       Impact factor: 3.902

Review 3.  Pentraxins in the activation and regulation of innate immunity.

Authors:  Kenji Daigo; Antonio Inforzato; Isabella Barajon; Cecilia Garlanda; Barbara Bottazzi; Seppo Meri; Alberto Mantovani
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

4.  Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients.

Authors:  Bodil Sjöberg; Sunna Snaedal; Peter Stenvinkel; Abdul Rashid Qureshi; Olof Heimbürger; Peter Bárány
Journal:  Clin Kidney J       Date:  2014-08

5.  Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.

Authors:  B Sjöberg; A R Qureshi; O Heimbürger; P Stenvinkel; L Lind; A Larsson; P Bárány; J Ärnlöv
Journal:  J Intern Med       Date:  2015-09-09       Impact factor: 8.989

6.  PTX3 in serum induces renal mesangial cell proliferation but has no effect on apoptosis.

Authors:  Danhuan Zhang; Minhui Xi; Lingyun Chen; Yanping Huang; Peiju Mao
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

Review 7.  Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review.

Authors:  Kenneth M Borow; R Preston Mason; Krishnaswami Vijayaraghavan
Journal:  Cardiorenal Med       Date:  2017-09-16       Impact factor: 2.041

8.  Study on Association of Pentraxin 3 and Diabetic Nephropathy in a Rat Model.

Authors:  Xuehai Chen; Jiao Luo; Minmin Wu; Zhuo Pan; Yue Xie; Hongwei Wang; Bicheng Chen; Hong Zhu
Journal:  J Diabetes Res       Date:  2018-03-13       Impact factor: 4.011

9.  Administration of Intravenous Iron Formulations Induces Complement Activation in-vivo.

Authors:  Bernardo Faria; Mariana Gaya da Costa; Felix Poppelaars; Casper F M Franssen; Manuel Pestana; Stefan P Berger; Mohamed R Daha; Carlo A J M Gaillard; Marc A Seelen
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.